The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity - PubMed (original) (raw)
. 2000 Aug 1;60(15):4167-74.
Affiliations
- PMID: 10945625
The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity
O Wildner et al. Cancer Res. 2000.
Abstract
In this study, we evaluated three herpes simplex virus-1 thymidine kinase (HSV-tk) carrying replication-competent adenoviral vectors with and without the Ad5 E1B 55 kDa gene to assess whether this gene product has an influence on their antitumor efficacy, replication kinetics, and potential hepatotoxicity. Furthermore, we assessed the efficacy of these vectors in combination with ganciclovir (GCV). When compared with wild-type adenovirus, the recombinant vectors, in particular the E1B 55 kDa-deleted vector Ad.TK(RC)(II), generated a more efficiently cytopathic effect in proliferating cells, independently of their p53 phenotype. In a s.c. A549 lung cancer xenograft model, the cytoreductive effect of Ad.TK(RC)(II) was enhanced when followed by GCV treatment. In contrast, the efficacy of both E1B 55 kDa-positive vectors could not be further improved by GCV. In an i.p. MDAH 2774 ovarian cancer xenograft tumor model, the survival of animals treated with a prototypical replication-deficient adenovirus expressing HSV-tk (Ad.TK) was improved compared to controls when followed by GCV. In contrast, the cytoreductive efficacy of the replication-competent vectors was diminished when combined with the virostatic GCV. However, the antitumor effect of all replication-competent vectors was superior to combination chemotherapy with paclitaxel and carboplatin. In both tumor models, the oncolytic effect of the E1B 55 kDa-positive vectors was greater than that of Ad.TK(RC)(II). In an attempt to assess the toxicity of these vectors in a nonpermissive host, the viruses were administered systemically to immunocompetent and immunodeficient mice. Greater hepatotoxicity was seen with i.v. administration of the replication-competent viruses than with Ad.TK and in immunocompetent hosts, suggesting involvement of the immune system in the induction of tissue damage. The E1B 55 kDa gene had no significant influence on the liver toxicity of the vectors in this system. At therapeutic doses, intratumoral or i.p. injection of all vectors was well tolerated. Importantly, these replication-competent HSV-tk-expressing vectors were highly susceptible to GCV, representing an effective fail-safe mechanism to abolish viral replication in a clinical setting. Controllable intratumoral viral replication holds promise as a new treatment modality for cancer.
Similar articles
- Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
Wildner O, Morris JC. Wildner O, et al. J Gene Med. 2000 Sep-Oct;2(5):353-60. doi: 10.1002/1521-2254(200009/10)2:5<353::AID-JGM130>3.0.CO;2-G. J Gene Med. 2000. PMID: 11045429 - Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Nanda D, et al. Cancer Res. 2001 Dec 15;61(24):8743-50. Cancer Res. 2001. PMID: 11751394 - Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.
Wildner O, Hoffmann D, Jogler C, Uberla K. Wildner O, et al. Cancer Gene Ther. 2003 Oct;10(10):791-802. doi: 10.1038/sj.cgt.7700638. Cancer Gene Ther. 2003. PMID: 14502232 - Gene therapy for malignant neoplasms of the CNS.
Culver KW. Culver KW. Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S6-9. Bone Marrow Transplant. 1996. PMID: 8971399 Review. - [New paradigm of herpes simplex virus type 1 thymidine kinase (HSV-TK)/ganciclovir (GCV)].
Nawa A, Ishida D, ChenHong L. Nawa A, et al. Nihon Rinsho. 2006 Mar;64 Suppl 3:345-9. Nihon Rinsho. 2006. PMID: 16615496 Review. Japanese. No abstract available.
Cited by
- Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
Hoffmann D, Wildner O. Hoffmann D, et al. BMC Biotechnol. 2006 Aug 3;6:36. doi: 10.1186/1472-6750-6-36. BMC Biotechnol. 2006. PMID: 16887042 Free PMC article. - ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.
Ries S, Korn WM. Ries S, et al. Br J Cancer. 2002 Jan 7;86(1):5-11. doi: 10.1038/sj.bjc.6600006. Br J Cancer. 2002. PMID: 11857003 Free PMC article. Review. - Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy.
Baril P, Martin-Duque P, Vassaux G. Baril P, et al. Br J Pharmacol. 2010 Feb;159(4):761-71. doi: 10.1111/j.1476-5381.2009.00412.x. Epub 2009 Oct 8. Br J Pharmacol. 2010. PMID: 19814733 Free PMC article. Review. - In vitro and in vivo inhibition of SK-N-MC neuroblastoma growth using cyclic nucleotide phosphodiesterase inhibitors.
Giorgi M, Leonetti C, Citro G, Augusti-Tocco G. Giorgi M, et al. J Neurooncol. 2001 Jan;51(1):25-31. doi: 10.1023/a:1006489020190. J Neurooncol. 2001. PMID: 11349877 - Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?
Dix BR, Edwards SJ, Braithwaite AW. Dix BR, et al. J Virol. 2001 Jun;75(12):5443-7. doi: 10.1128/JVI.75.12.5443-5447.2001. J Virol. 2001. PMID: 11356950 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous